



ORIGINAL ARTICLE

Clinical and genetic diagnosis of familial hypertrophic cardiomyopathy: Results in pediatric cardiology[☆]



Bárbara Cardoso*, Inês Gomes, Petra Loureiro, Conceição Trigo, Fátima F. Pinto

Serviço de Cardiologia Pediátrica, Hospital Santa Marta, Centro Hospitalar de Lisboa Central, Lisboa, Portugal

Received 23 January 2016; accepted 26 September 2016

Available online 6 March 2017

KEYWORDS

Children;
Hypertrophic
cardiomyopathy;
Genetic testing;
Penetrance

Abstract

Introduction: Hypertrophic cardiomyopathy (HCM) is most often of autosomal dominant inheritance with incomplete penetrance and variable expression. The main purpose of family screening is to identify relatives with unrecognized HCM and to monitor those at risk for disease, in order to minimize complications and to assess risk of sudden cardiac death. The ESC and ACCF/AHA guidelines on the diagnosis and management of HCM recommend the screening of child relatives from the age of 10–12 years.

Objectives: We studied the outcome of clinical screening and genetic testing of child probands and relatives (<18 years of age) from families with HCM and assessed the age-related penetrance of HCM during the follow-up of these young relatives.

Methods and Results: Twenty patients from ten families were included between 2004 and 2013, consisting of three probands and 17 first-degree relatives (80% male; median age 10 years). Fourteen child relatives were mutation carriers (70%; median age eight years). Seven (50%) of the 14 mutation carriers were diagnosed with HCM at initial assessment. At-risk child relatives were defined as those with a positive mutation but a negative phenotype at enrollment.

After 3.5 ± 0.8 years of follow-up, two of the phenotype-negative mutation carriers developed HCM at 10 and 15 years of age (28% penetrance rate).

Conclusions: The penetrance of HCM in phenotype-negative child relatives was 28% after 3.5 years of follow-up. This underlines the need for long-term monitoring of mutation carriers irrespective of the presence of a positive phenotype.

© 2016 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights reserved.

[☆] Please cite this article as: Cardoso B, Gomes I, Loureiro P, Trigo C, F. Pinto F. Diagnóstico clínico e genético de miocardiopatia hipertrófica familiar: resultados em cardiologia pediátrica. Rev Port Cardiol. 2017;36:155–165.

* Corresponding author.

E-mail address: barbarcardoso.ba@gmail.com (B. Cardoso).

PALAVRAS-CHAVE

Crianças;
 Miocardiopatia
 hipertrófica familiar;
 Diagnóstico genético;
 Penetrância

Diagnóstico clínico e genético de miocardiopatia hipertrófica familiar: resultados em cardiologia pediátrica**Resumo**

Introdução: A miocardiopatia hipertrófica (MCH) é uma patologia com transmissão essencialmente autossômica dominante, expressão clínica variável e penetrância incompleta. O rastreio familiar tem por objetivo identificar a ocorrência ou o risco de desenvolvimento da doença nos parentes em primeiro grau do caso índice. As normas de orientação da ESC e da ACCF/AHA recomendam a avaliação dos familiares em idade pediátrica a partir dos 10-12 anos.

Objetivos: Avaliaram-se os resultados de um programa de rastreio pediátrico de MCH familiar e o valor preditivo do seu estudo genético. Foi ainda aferida a penetrância fenotípica ao longo do tempo de seguimento destas crianças.

Métodos e resultados: Foram incluídas 20 pertencentes a dez famílias (2004-2013). Três das crianças constituíram-se como o caso índice, sendo as restantes parentes em primeiro grau de um doente com MCH (80% sexo masculino; idade mediana = 10 anos). Catorze crianças eram portadoras de mutação de um gene sarcomérico (70%; idade mediana = 8 anos). Sete (50%) dos 14 portadores de mutação apresentavam fenótipo positivo na primeira avaliação.

Foram definidos como «familiares em risco» aqueles com teste genético positivo, mas com fenótipo normal à apresentação. Após $3,5 \pm 0,8$ anos de seguimento, duas das crianças fenótipo negativo portadoras de mutação (gene *MYBPC3*) desenvolveram MCH, aos dez e 15 anos de idade (28% de taxa de penetrância).

Conclusões: A penetrância de MCH em crianças com fenótipo normal à apresentação foi de 28% após 3,5 anos de seguimento. Tal sublinha a importância da avaliação longitudinal dos portadores de mutação de genes sarcoméricos, independentemente da presença de fenótipo patológico.

© 2016 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Todos os direitos reservados.

List of abbreviations

ACCF/AHA	American College of Cardiology Foundation/American Heart Association
BMI	body mass index
BSA	body surface area
CI	confidence interval
ECG	electrocardiogram
ESC	European Society of Cardiology
ICD	implantable cardioverter-defibrillator
HCM	hypertrophic cardiomyopathy
HGMD	Human Gene Mutation Database
LV	left ventricular
LVOT	left ventricular outflow tract
PCR	polymerase chain reaction
QTc	corrected QT
RR	relative risk
SAM	systolic anterior movement
SCD	sudden cardiac death
VT	ventricular tachycardia

Introduction

Hypertrophic cardiomyopathy (HCM) is most often of autosomal dominant inheritance with variable expression and age-related incomplete penetrance.¹

Its clinical expression is heterogeneous, ranging from asymptomatic to severe heart failure symptoms or sudden cardiac death (SCD).²

The main purpose of family screening is to identify first-degree relatives of the proband with or at risk of developing the disease.

The latest guidelines of the European Society of Cardiology (ESC) and of the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) recommend screening of child relatives from the age of 10-12 years.^{3,4}

It is estimated that a mutation in the genes coding for sarcomeric proteins can be identified in 50-60% of cases of familial HCM.⁵ However, in children with a negative phenotype, the prognostic value of identifying such mutations is unclear.

We studied the outcome of screening for familial HCM in a tertiary pediatric cardiology reference center and assessed the predictive value of genetic testing. We also analyzed the age-related penetrance of the disease during the follow-up of these young relatives.

Methods

Study population

We analyzed all cases of familial HCM followed in specialist consultations in a tertiary pediatric cardiology reference center between 2004 and 2013. All child relatives under the age of 18 of a proband with a positive genetic test for sarcomeric gene mutations were included.

Referral of first-degree relatives of a proband diagnosed with HCM was made mainly following cardiology consultation in the same center; when the proband was a child, siblings were referred for pediatric cardiology consultation and the parents for cardiology consultation.

All patients were also referred for genetic consultation in the same center.

Clinical assessment and genetic testing

Initial assessment of the study population included clinical observation, 12-lead resting ECG, transthoracic echocardiogram and genetic screening for the eight most common sarcomeric gene mutations associated with HCM (in *MYH7*, *MYL2*, *MYL3*, *MYBPC3*, *TNNI3*, *TNNT2*, *TPM1* and *ACTC1*).

Screening for mutations in the above genes (entire coding region, including intron/exon boundaries) was performed using polymerase chain reaction (PCR) technology with direct sequencing (combination of next-generation sequencing with a minimum of 30× coverage and Sanger sequencing) of the PCR products. This method has an analytical sensitivity of 99% for the detection of nucleotide substitutions and small deletions and insertions.

The ClinVar database and the Human Gene Mutation Database (HGMD) were used to classify the pathogenicity of DNA variants. The bioinformatics tools PolyPhen-2 and Mutation Taster were used to predict the disease-causing potential of mutations that had not been previously described or genetic variants of uncertain significance by assessing their functional effects.

Children with more than one mutation were classified as having a compound genotype.

Two-dimensional, M-mode and Doppler echocardiography were performed in accordance with the guidelines of the American Society of Echocardiography.⁶

Dimensions of the cardiac chambers, interventricular septum and left ventricular (LV) posterior wall, mitral valve systolic anterior movement (SAM) and LV outflow tract (LVOT) gradient were determined, at rest and during the Valsalva maneuver. LVOT obstruction was defined as a resting gradient of ≥ 30 mmHg.³

An echocardiographic diagnosis of HCM was made when the maximum LV posterior wall thickness was greater than twice the standard deviation of the predicted mean adjusted for body surface area (BSA).³ BSA was calculated according to the Haycock formula.⁷

The electrocardiogram (ECG) was analyzed for QRS axis deviation, T-wave inversion of >1 mm, ST-segment depression of >2 mm and S wave $>$ R wave in V4. Overall QRS amplitude, limb-lead QRS amplitude sum, 12-lead QRS amplitude-duration product, and corrected QT (QTc) according to Bazett's formula were calculated.⁸

SCD risk was stratified using the model proposed by Östman-Smith et al.⁹ The patients were scored from 1 to 3 on the eight parameters analyzed (maximum score 14), a total score of ≥ 6 indicating high risk. Although this predictive model was developed for adults with HCM, the authors used the same model in a pediatric population and reported similar predictive value (unpublished study, presented at the 46th Annual Meeting of the Association for European Paediatric and Congenital Cardiology, Istanbul, Turkey, 23-26 May 2012).

The following risk factors for SCD were also analyzed¹⁰:

- family history of SCD: non-traumatic premature death (at age <40 years); death within an hour of symptom onset in the absence of previous symptoms, including unexpected or unwitnessed nocturnal death or equivalent, such as need for cardiopulmonary resuscitation or appropriate implantable cardioverter-defibrillator (ICD) shock;
- unexplained syncope of non-neurocardiogenic etiology;
- nonsustained ventricular tachycardia (VT): one or more episodes of ≥ 3 consecutive ventricular extrasystoles with heart rate of >120 bpm, lasting <30 s during exercise testing or 24-h Holter monitoring;
- severe LV hypertrophy: maximum LV wall thickness of ≥ 30 mm or z-score of ≥ 6.3 .

Follow-up

Individuals with positive genotype and phenotype were classified as affected and followed in pediatric cardiology consultations every six months.

Carriers of sarcomeric gene mutations, genetic variants of uncertain significance or mutations not previously described as associated with HCM and with no phenotypic manifestations of the disease were classified as at risk of developing HCM. Genetic study was pending in one case, who was considered at risk of developing the disease. These children were followed in annual consultations.

Those with a negative phenotype and no mutation were not considered at risk of HCM and were discharged from follow-up.

Follow-up consultations included clinical assessment, 12-lead ECG and transthoracic echocardiogram, and 24-h Holter monitoring was requested whenever deemed clinically necessary.

All children aged >7 years underwent conventional exercise testing, and two also underwent exercise echocardiography.

Statistical analysis

Continuous variables with normal distribution are presented as means and standard deviation and as medians, minimum and maximum otherwise. Categorical variables are expressed as frequencies and percentages.

Results

Twenty children from ten families were included in this study of familial HCM (Figures 1–3), of whom three were probands and the remainder first-degree relatives of a patient with HCM (80% male; median age 10 years [1 month - 16 years]).

The reasons for referral for pediatric cardiology consultation of the three probands were ECG alterations, chest pain on exertion and heart murmur. There was a family history of SCD in families I, IV and V.

Clinical findings at recruitment (Table 1)

Most children (n=16; 80%) were asymptomatic at initial assessment; an episode of unexplained syncope was reported in two children and two others reported chest pain on exertion.

Seven (50%) of the 14 mutation carriers presented a positive phenotype on initial assessment; LV systolic function was preserved in all of them.

No patient presented significant obstruction at rest. Significant LV obstruction was induced by exercise in one patient, who was medicated with beta-blockers and advised to restrict physical activity.

Eight children (40%) were carriers of a sarcomeric gene mutation, but had no phenotypic manifestation of the disease at initial assessment. They were considered at risk of developing HCM.

Five (25%) of the relatives assessed presented negative phenotype and genotype, and were thus considered not at risk of developing HCM and discharged from follow-up.

Results of genetic testing (Table 2)

At initial assessment, 14 children (70%) - 80% male, median age eight years (one month - 16 years) - were carriers of one or more mutations in sarcomeric genes: *MYBPC3* (n=14, 78%), *MYH7* (n=2, 11%), *TNNT2* (n=1, 5.5%) and *MYL3* (n=1, 5.5%).

One patient (case 8, family IV) presented two heterozygous mutations in *MYBPC3* (exons 19 and 32), one previously described in HCM (p.Gly1206Asp) and the other a genetic variant of uncertain significance (p.Asp610Asn) but predicted to be pathogenic by PolyPhen-2 and Mutation Taster.

Two brothers (cases 12 and 13, family VII) presented two mutations in *MYBPC3* (exon 6 and exon 8), one previously described in HCM (p.Glu258Lys) and the other (p.Gly279Ala) predicted to be benign by PolyPhen-2 and Mutation Taster.

In case 19 (family X) a heterozygous mutation (p.Ala149Asp) in exon 4 of *MYBPC3* and another mutation (p.Glu49STOP) in exon 2 of *MYL3* were detected. The mutation p.Ala149Asp has not been previously described in HCM but is predicted to be benign by PolyPhen-2 and Mutation Taster. The mutation p.Glu49STOP has also not been described in HCM, but given the consequences for the protein sequence, it is assumed that it could be disease-causing.

Cases 17 and 18 (family IX) presented positive genetic study for LEOPARD syndrome, a pathogenic mutation being identified in exon 12 of *PTPN11* (c.1403C>T; p.Thr468Met).




Figure 1 Genograms of families under study at initial assessment y: years.




Figure 2 Genograms of families under study at initial assessment y: years.

A heterozygous mutation in exon 17 of gene *MYBPC3* (p.Gly507Arg) was also detected in these two children; this is a genetic variant of uncertain significance, but predicted to be disease-causing by PolyPhen-2 and Mutation Taster.).

One patient presented a compound genotype, with more than one mutation in a sarcomeric gene.

Four patients had an electrocardiographic risk score of ≥ 6 (Table 4)

Risk for SCD was analyzed in the seven patients with positive phenotype and genotype, three of whom presented no conventional risk factor (Table 3). Two of the three patients with an electrocardiographic risk score of <6 presented no other risk factors for SCD.

Patient characteristics at last assessment (Table 5)

Mean follow-up was 3.5 ± 0.8 years (6 months - 9.5 years).

At the end of follow-up, two children with negative phenotype but carrying a mutation in *MYBPC3* developed HCM at 10 and 15 years of age (28% penetrance).

All patients diagnosed with HCM at initial assessment still had this diagnosis at the last assessment.

There were no deaths during follow-up. One patient underwent implantation of an ICD as primary prevention following an episode of nonsustained VT on 24-hour Holter monitoring. This patient had three conventional risk factors (syncope, severe LV hypertrophy and a family history of SCD




Figure 3 Genograms of families under study at initial assessment y: years.

Table 1 Characteristics of the study population.

Case	Family	Proband	Gender	Age (years)	Reason for referral	Symptoms	Malformation syndrome	Phenotype	Genotype	Classification
1	I	Father	M	14	FH	Chest pain on exertion	-	HCM	+	Affected
2	II	Brother	M	7	FH	0	-	N	+	At risk
3	II	Proband	M	12	ECG abnormalities	0	-	HCM	+	Proband
4	II	Brother	M	10	FH	0	-	N	-	Not at risk
5	III	Father	F	5	FH	0	-	N	+	At risk
6	III	Father	M	2	FH	0	-	N	+	At risk
7	IV	Paternal aunt	M	11	FH	0	-	N	-	Not at risk
8	IV	Paternal aunt	M	12	FH	Syncope	-	HCM	+	Affected
9	V	Father	F	5	FH	0	-	N	+	At risk
10	V	Father	M	7	FH	0	-	N	+	At risk
11	VI	Father	M	13	FH	Syncope	-	HCM	+	Affected
12	VII	Proband	M	8	Chest pain on exertion	Chest pain on exertion	-	HCM	+	Proband
13	VII	Brother	M	10	FH	0	-	N	+	At risk
14	VIII	Father	F	14	FH	0	-	N	-	Not at risk
15	VIII	Father	M	7	FH	0	-	N	-	Not at risk
16	IX	Brother	F	0.08	FH	0	LEOPARD syndrome	N	?	At risk
17	IX	Brother	M	5	FH	0	LEOPARD syndrome	N	+	At risk
18	IX	Proband	M	0.1	Murmur	0	LEOPARD syndrome	HCM	+	Proband
19	X	Father	M	16	FH	0	-	HCM	+	Affected
20	X	Father	M	11	FH	0	-	N	-	Not at risk

F: female; FH: family history; HCM: hypertrophic cardiomyopathy; M: male; N: normal.

Table 2 Sarcomeric gene mutations identified in the study population.

Case	Family	Mutated gene	cDNA alteration	Protein alteration	Clinical significance	
1	I	Exon 27 of <i>MYBPC3</i>	c.2864_2865delCT	p.Pro955ArgfsX95	Disease-causing mutation. HGMD CD982813	
2	II	Exon 18 of <i>MYBPC3</i>	c.1684G>A	p.Ala562Thr	Genetic variant of uncertain significance	PolyPhen-2: possibly damaging Mutation Taster: disease-causing
3	II	Exon 18 of <i>MYBPC3</i>	c.1684G>A	p.Ala562Thr	Genetic variant of uncertain significance	PolyPhen-2: possibly damaging Mutation Taster: disease-causing
4	II	-	-	-		
5	III	Exon 22 of <i>MYH7</i>	c.2539_2541delAAG	p.Lys847del	Pathogenic mutation HGMD CD046025 HGMD CM0910620	
6	III	Exon 22 of <i>MYH7</i>	c.2539_2541delAAG	p.Lys847del	Pathogenic mutation HGMD CD046025 HGMD CM0910620	
7	IV	-	-	-		
8	IV	Exon 19 of <i>MYBPC3</i> Exon 32 of <i>MYBPC3</i>	c.1828G>A e c.3617G>A	p.Asp610Asn p.Gly1206Asp	Genetic variant of uncertain significance Pathogenic mutation HGMD CM057198	PolyPhen-2: probably damaging Mutation Taster: disease-causing
9	V	Exon 4 of <i>MYBPC3</i>	c.458C>A	p.Pro153His	Undescribed mutation	PolyPhen-2: Probably damaging Mutation Taster: Disease-causing
10	V	Exon 27 of <i>MYBPC3</i>	c.2827C>T	p.Arg943STOP	Pathogenic mutation HGMD CM032959	
11	VI	Exon 11 of <i>TNNT2</i>	c.458_489del3	p.Glu163del	Pathogenic mutation HGMD CD9518665	
12	VII	Exon 6 of <i>MYBPC3</i>	c.772G>A	p.Glu258Lys	Pathogenic mutation HGMD CM981322	
		Exon 8 of <i>MYBPC3</i>	c.836G>C	p.Gly279Ala	Genetic variant of uncertain significance HGMD CM031257	PolyPhen-2: benign Mutation Taster: polymorphism
13	VII	Exon 6 of <i>MYBPC3</i>	c.772G>A	p.Glu258Lys	Pathogenic mutation HGMD CM981322	
		Exon 8 of <i>MYBPC3</i>	c.836G>C	p.Gly279Ala	Genetic variant of uncertain significance HGMD CM031257	PolyPhen-2: benign Mutation Taster: polymorphism
14	VIII	-	-	-		
15	VIII	-	-	-		
16	IX	Pending	Pending	Pending		
17	IX	Exon 17 of <i>MYBPC3</i>	c.1519G>A	p.Gly507Arg	Genetic variant of uncertain significance HGMD CM032598	PolyPhen-2: probably damaging Mutation Taster: disease-causing
18	IX	Exon 17 of <i>MYBPC3</i>	c.1519G>A	p.Gly507Arg	Genetic variant of uncertain significance HGMD CM032598	PolyPhen-2: probably damaging Mutation Taster: disease-causing
19	X	Exon 4 of <i>MYBPC3</i> Exon 2 of <i>MYL3</i>	c.446C>A c.145G>T	p.Ala149Asp p.Glu49STOP	Undescribed mutation Undescribed mutation	PolyPhen-2: benign Mutation Taster: polymorphism Mutation Taster: disease-causing
20	X	-	-	-		

MYBPC3: myosin binding protein C; MYL3: myosin light chain 3; MYH7: myosin heavy chain 7; TNNT2: cardiac troponin T.

Table 3 Stratification of risk of sudden cardiac death in patients with positive phenotype and genotype.

Case	Family	Conventional risk factor	Genotype	LVOT obstruction (max. LVOT gradient)	Electrocardiographic risk score
1	I	FH of SCD	-	-	8
3	II	Diastolic IVS >30 mm	-	-	8
8	IV	Syncope; FH of SCD	Compound genotype ^a	-	7
11	VI	Syncope; diastolic IVS >30 mm; FH of SCD	-	-	12
12	VII	-	-	SAM, exercise-induced intraventricular gradient 100 mmHg	3
18	IX	-	-	-	4
19	X	-	-	-	3

FH: family history; IVS: interventricular septum; LVOT: left ventricular outflow tract; SAM: systolic anterior movement; SCD: sudden cardiac death.

^a Compound genotype: more than one mutation in the same gene.

in a paternal aunt diagnosed with HCM) and an electrocardiographic risk score of 12 (Table 3).

Discussion

HCM has an estimated annual incidence of 0.3-0.5 per 100 000 children.^{3,11}

Familial HCM in adults is caused by mutations in cardiac sarcomere protein genes in up to 60% of cases,³ but its etiology is more complex and variable in children.

Of 855 children with HCM in the Pediatric Cardiomyopathy Registry, the etiology was known in only 25.8% of cases: 9% were associated with malformation syndromes, 8.7% with inborn errors of metabolism and 7.5% with neuromuscular disorders.¹² It is estimated that around a third of children

with HCM have familial disease, the result of mutations in genes coding for sarcomeric proteins.⁹

Genetic testing in familial hypertrophic cardiomyopathy

Over 1400 mutations in 11 genes encoding proteins of the myofilaments or Z-disc of sarcomeres have been described.⁵

A sarcomeric mutation is identified in 50-60% of cases of familial HCM.⁵ When a pathogenic mutation is identified in a patient, genetic testing is a cost-effective method of family screening, the purpose of which is to detect the presence of or assess the risk of developing the disease in first-degree relatives of the proband, in order to initiate early treatment and stratify the risk of SCD.

Table 4 Electrocardiographic risk scores in patients with positive phenotype and genotype.

ECG parameter	Score	Case 1	Case 3	Case 8	Case 11	Case 12	Case 18	Case 19
QRS axis deviation	1 point	1	0	0	1	0	1	0
T-wave inversion in limb leads ^a	1 point	0	1	1	1	0	0	0
T-wave inversion in precordial leads ^a	2 points	2	1	1	1	0	0	0
ST depression >2 mm	2 points	0	0	1	2	0	0	0
Dominant S in V4	2 points	1	0	0	0	0	0	0
Limb-lead QRS amplitude sum	>7.7 mV=1 point >10 mV=2 points >12 mV=3 points	0	3	1	3	0	0	0
12-lead QRS amplitude-duration sum	>2.2 mV.s=1 point >2.5 mV.s=2 points >3 mV.s=3 points	3	3	3	3	3	3	3
QTc >440 ms	1 point	1	0	0	1	0	0	0
Total score		8	8	7	12	3	4	3

QTc: corrected QT.

^a Maximum points for T-wave anomalies: 2; maximum score: 14.

Table 5 Patient characteristics at last assessment.

Case	Family	Age (years)	Phenotype	Symptoms	Complications	Classification
1	I	16	HCM	0	-	Affected
2	II	10	HCM	0	-	Affected
3	II	19	HCM	0	-	Proband
5	III	6	N	Palpitations	-	At risk
6	III	4	N	0	-	At risk
8	IV	14	HCM	0	-	Affected
9	V	8	N	0	-	At risk
10	V	9	N	0	-	At risk
11	VI	17	HCM	0	ICD	Affected
12	VII	18	HCM	0	-	Proband
13	VII	15	HCM	0	-	Affected
16	IX	3	N	0	-	At risk
17	IX	12	N	0	-	At risk
18	IX	7	HCM	0	-	Proband
19	X	17	HCM	0	-	Affected

HCM: hypertrophic cardiomyopathy; ICD: implantable cardioverter-defibrillator; N: normal.

The latest ESC and ACCF/AHA guidelines recommend the assessment of child relatives from the age of 10-12 years.^{3,4} However, in families with early-onset disease, clinical evaluation and genetic testing may be appropriate before this age.³

At present, genetic study is mainly used as an aid in deciding whether to maintain relatives of the proband in clinical and echocardiographic follow-up.^{3,4}

In our sample, five children (25%) presented negative phenotype and genotype and were discharged from regular follow-up. This approach reassures non-affected relatives as to the likelihood of developing the disease and avoids unnecessary consultations.

Children with positive genotype were divided into two groups: those with positive phenotype (n=7, 35%) were classified as affected and those with negative phenotype (n=8, 40%) were classified as at risk.

The ClinVar database and HGMD were used to classify the disease-causing potential of DNA variants, which showed that the mutations identified in eight cases had been previously described as pathogenic. PolyPhen-2 and Mutation Taster were used in cases of previously undescribed mutations (n=3) and of genetic variants of uncertain significance (n=7), to assess their functional effects.

We opted to include patients from family IX in this study despite a genetic diagnosis of LEOPARD syndrome, which in itself would explain the HCM phenotype, since they also presented a heterozygous mutation in exon 17 of gene *MYBPC3* (p.Gly507Arg). This is a genetic variant of uncertain significance, likely to be pathogenic according to PolyPhen-2 and Mutation Taster, but the disease-causing potential of this sarcomeric mutation remains to be confirmed.

It was our policy to maintain follow-up of patients with genetic variants of uncertain significance and those with previously undescribed mutations, even in the absence of phenotypic manifestations of the disease, as being at risk.

However, besides serial assessments, the clinical management of carriers of sarcomeric gene mutations with negative phenotype has not been established.³ According

to the latest international guidelines, children with positive genotype/negative phenotype should be assessed every 12-18 months, while adults only need to be assessed every 2-5 years.³

Carriers of sarcomeric gene mutations with no phenotypic expression of the disease have a low risk of adverse cardiac events, a recent study reporting an SCD rate of 0.13% per person-year.¹³

Risk stratification of sudden cardiac death

The annual risk of SCD in HCM patients is estimated at 1%.¹³ However, a Danish study carried out between 2000 and 2006 showed a risk of <0.1% per person-year in individuals aged 1-35 years.¹⁴

The latest ESC guidelines indicate the following as major risk factors for SCD in children with HCM: very severe LV hypertrophy (defined as maximum LV wall thickness of ≥ 30 mm or z-score ≥ 6), unexplained syncope, nonsustained VT, and family history of SCD.³

We opted to stratify risk of SCD in affected relatives only, as recommended in the ACCF/AHA guidelines.⁴

Besides conventional risk factors, we analyzed other factors described in the literature: LVOT obstruction⁹ and compound genotype.^{3,15}

We also applied the electrocardiographic risk score proposed by Östman-Smith et al.,⁹ which was significantly associated with SCD in their population of adults with HCM, with high sensitivity (85%) and specificity (100%). This predictive model assesses the presence of QRS axis deviation, pathological T-wave inversion, ST-segment depression, dominant S in V4, limb-lead QRS amplitude sum, 12-lead QRS amplitude-duration product, and QTc.

It is interesting to note that the only patient in our sample with complications (requiring ICD implantation) had the highest electrocardiographic risk score, as well as three conventional risk factors.

Phenotypic expression of hypertrophic cardiomyopathy

The clinical expression of HCM is determined by a complex interaction between genetic, epigenetic and environmental factors. As with other diseases of autosomal dominant inheritance, HCM shows considerable phenotypic variability, even within the same family.

The following have been suggested as pre-phenotypic manifestations of HCM in carriers of sarcomeric gene mutations: myocardial crypts, elongation of the mitral leaflets, diastolic dysfunction, increased collagen deposition and myocardial fibrosis.^{3,4}

Mutation penetrance of HCM also varies over time and may be substantially delayed, but increases with age, although always to less than 100%.⁵

A recent study reported an incidence of manifest HCM in carriers of sarcomeric mutations aged under 40 of <0.10% per person-year.¹³

Studies in children have shown a penetrance of phenotypic expression of 6-31% in carriers of sarcomeric gene mutations after a follow-up of up to 12 years.^{2,16}

In our sample, two phenotype-negative mutation carriers developed HCM after 3.5±0.8 years of follow-up, at age 10 and 15 years. The resulting penetrance rate of 28% is in agreement with the literature.

This highlights the importance of long-term follow-up of carriers of sarcomeric gene mutations, with a view to the eventual development of therapies that may modulate expression of the disease.

Study limitations

The study has the limitations inherent to its retrospective design and small sample size.

It is important to stress that age-related penetrance probably depends on multiple factors, including gender, race and genotype. Our sample consisted solely of Caucasian children with mutations in four sarcomeric genes (*MYBPC3*, *MYH7*, *TNNT2* and *MYL3*).

The small number of complications in our study population does not enable associations to be established with the risk factors identified.

Conclusion

When a pathogenic mutation is detected in a patient with HCM, genetic testing is an effective means of family screening, as this identifies relatives at risk of developing the disease and those who can be discharged from follow-up.

The penetrance of HCM in child relatives with positive genotype/negative phenotype at initial assessment was 28% after 3.5 years of follow-up. This underlines the need for longitudinal long-term monitoring of sarcomeric gene mutation carriers, irrespective of the presence of a positive phenotype.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Maron BJ, Seidman JG, Seidman CE. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. *J Am Coll Cardiol.* 2004.
2. Jensen MK, Havndrup O, Christiansen M, et al. Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing. *Circulation.* 2013;127:48–54.
3. Elliott PM, Anastakis A, Borger MA, et al. ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J.* 2014;35:2733–79.
4. Members Writing Committee, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Thorac Cardiovasc Surg.* 2011;142:e153–203.
5. Ho CY, Charron P, Richard P, et al. Genetic advances in sarcomeric cardiomyopathies: state of the art. *Cardiovasc Res.* 2015;105:397–408.
6. Lai WW, Geva T, Shirali GS, et al. Guidelines and standards for performance of a pediatric echocardiogram: a report from the Task Force of the Pediatric Council of the American Society of Echocardiography. *J Am Soc Echocardiogr.* 2006;19:1413–30.
7. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. *J Pediatr.* 1978;93:62–6.
8. Bazett H. An analysis of the time-relations of electrocardiograms. *Heart.* 1920.
9. Östman-Smith I, Wisten A, Nylander E, et al. Electrocardiographic amplitudes: a new risk factor for sudden death in hypertrophic cardiomyopathy. *Eur Heart J.* 2010.
10. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high-risk patients. *J Am Coll Cardiol.* 2000;36:2212–8.
11. Wilkinson J, Landy D, Colan S. The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years. *Heart Fail Clin.* 2010.
12. Colan S, Lipshultz S, Lowe A. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. *Circulation.* 2007.
13. Christiaans I, Birnie E, Bonsel GJ, et al. Manifest disease, risk factors for sudden cardiac death, and cardiac events in

- a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. *Eur Heart J.* 2011;32:1161–70.
14. Winkel BG, Holst AG, Theilade J, et al. Nationwide study of sudden cardiac death in persons aged 1-35 years. *Eur Heart J.* 2011;32:983–90.
 15. Ingles J, Doolan A, Chiu C, et al. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. *J Med Genet.* 2005.
 16. Maron BJ, Spirito P, Wesley Y, et al. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. *N Engl J Med.* 1986;315:610–4.